Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 13/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4313000 | 0.93 | CCR3 (0.43) | CCR3FAAH | |
| SCHEMBL4308566 | 0.89 | CCR3 (0.42) | CCR3FPR2PROKR1FAAH | |
| SCHEMBL4306525 | 0.89 | CCR3 (0.40) | CCR3FPR2PROKR1ENPP2FAAH | |
| SCHEMBL4309687 | 0.88 | CCR3 (0.39) | CCR3FPR2PROKR1ENPP2EPHX2 | |
| SCHEMBL4308693 | 0.83 | SPR (0.44) | ENPP2SLC6A2SLC6A4SLC6A3FAAH | |
| SCHEMBL4306625 | 0.83 | CCR3 (0.39) | CCR3FPR2PROKR1ENPP2 | |
| SCHEMBL4311485 | 0.81 | KCNH2 (0.45) | FAAH | |
| SCHEMBL4314261 | 0.81 | HSD11B1 (0.51) | FAAH | |
| SCHEMBL4308023 | 0.81 | CCR3 (0.41) | CCR3FAAH | |
| SCHEMBL4314093 | 0.80 | CCR3 (0.37) | CCR3ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879873-B1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-10-09 | — | — | EP | claimed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | claimed |
| US-20060258718-A1 | Neurotherapeutic azole compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2006-11-16 | — | — | US | claimed |
| EP-1879873-B1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-10-09 | — | — | EP | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| EP-1879873-A1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK Holdings Co., Ltd. (KR) | 2008-01-23 | — | — | EP | disclosed |
| US-20060258718-A1 | Neurotherapeutic azole compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2006-11-16 | — | — | US | disclosed |
| WO-2006112685-A1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK HOLDINGS CO., LTD. (KR) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258718-A1 | Neurotherapeutic azole compounds | CHRNA10, CHRNA4, CHRNA3 | CCR3 3607/4885FPR2 3737/4885PROKR1 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.